HOME >> MEDICINE >> NEWS
Predicting the outcome of drug-induced liver disease

Drug-induced liver disease (DILD), a potential complication seen with some medications, is usually not life-threatening, but may occasionally be more severe with a high mortality, requiring a liver transplant in selected cases. During the last decade, drug-induced liver injury has led to the withdrawal of a number of drugs from the market. Hy's rule, an observation by the late Dr. Hyman Zimmerman, states that the combination of high liver cell damage as measured by liver enzymes and jaundice induced by a drug is associated with a fatality rate of 10-50 percent. This rule has been advocated by the FDA for assessing the liver toxicity of newly developed drugs, but it has never been scientifically validated.

A study by Einar Bjrnsson, M.D., Ph.D. and Rolf Olsson, M.D., Ph.D. of the department of internal medicine at Sahlgrenska University Hospital in Gothenburg, Sweden and published in the August 2005 issue of Hepatology, analyzed reports of suspected drug-induced liver injury received by the Swedish Adverse Drug Reactions Advisory Committee (SADRAC) in order to evaluate the validity of Hy's rule and determine what factors might predict the outcome of different forms of DILD.

Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD), published by John Wiley & Sons, Inc. is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

A total of 784 reports were included in the analysis, each with bilirubin greater than twice upper normal limits and ALT (a liver enzyme that when elevated indicates liver damage) greater than three times upper normal limits. Of these, 409 cases had hepatocellular or HC liver injury (damage to liver cells); while 206 had cholestatic (bile flow) injury and 169 had mixed liver injury. In 633 cases, one drug was suspected of causing the liver injury, while in 151 cases more t
'"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
18-Jul-2005


Page: 1 2

Related medicine news :

1. Predicting danger of flu pandemic rests on differences in affected population, says O.R. Forum
2. Predicting the quality of life for older adults
3. Predicting the risk of rheumatoid arthritis for early arthritis patients
4. Predicting an answer to the threat of flooding
5. Predicting outcomes for kidney transplant patients
6. Predicting successful outcomes in living-donor liver transplants
7. Predicting cardiovascular problems in liver transplant patients
8. Predicting the risk of death in patients with known coronary artery disease
9. Predicting the future of primary care in England
10. Predicting serious cardiac outcomes
11. Comparison of obstetric outcomes between on-call and patients own obstetricians

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... British Columbia (PRWEB) , ... June 28, 2017 ... ... CNZCF) (FSE: ZEON) is pleased to announce that a two year study conducted ... the Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As ...
(Date:6/28/2017)... OH (PRWEB) , ... June 28, 2017 , ... ... of Hamilton County and the surrounding regions access to insurance assistance and financial ... with Matthew 25: Ministries to assist families in the region facing financial crisis. ...
(Date:6/28/2017)... Cincinnati, OH (PRWEB) , ... June 28, 2017 ... ... and financial consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is ... help provide temporary lodgings for families with children receiving treatment in nearby hospitals. ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 ... survey data released today by the American Society for Dermatologic Surgery ... the percentage of consumers considering a cosmetic medical procedure has doubled since 2013. ...
(Date:6/27/2017)... ... , ... Harbour , a DAO (decentralized autonomous organization) that harnesses the ... their technical specifications . , 2017 has seen an explosion of token launches ... which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, ...
Breaking Medicine News(10 mins):
(Date:6/27/2017)...  Therapix Biosciences Ltd. (Nasdaq: TRPX ) ... development of cannabinoid-based drugs, today announced that the Company ... New York, NY on Wednesday, ... offering (IPO) of American Depository Shares (ADSs) listed on ... Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, ...
(Date:6/27/2017)... --  NuEyes (NuEyes Technologies Inc.) today announced that it ... in helping the legally blind live more independent lives. NuEyes works ... developer of augmented, virtual and mixed reality smartglasses and the ... funding amount was provided by strategic partners as well as ... Abu Dhabi , New York ...
(Date:6/20/2017)... Netherlands and LAGUNA HILLS, Calif. ... the presentation of new data that validate the use ... risk stratify patients with multiple myeloma (MM). In a ... the European Hematology Association (EHA) in Madrid, ... value of MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology:
Cached News: